DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis

Oncotarget

Volumn 7, Issue 12, 2016, Pages 14188-14198

  Ji, Yan Mei ^a   Zhou, Xue Feng ^b   Zhang, Jun ^a   Zheng, Xiang ^a   Li, Sheng Bao ^a   Wei, Zhi Qiang ^a   Liu, Tao ^a   Cheng, Dong Liang ^a   Liu, Ping ^a   Song, Kuncheng ^c   Tan, Tao ^c   Zhu, Hua ^c   Guo, Jia Long ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

DEPTOR; Esophageal squamous cell carcinoma; mTOR; Proliferation

Indexed keywords

DEP DOMAIN CONTAINING MAMMALIAN TARGET OF RAPAMYCIN INTERACTING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; DEPTOR PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; DOWN REGULATION; ENZYME PHOSPHORYLATION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL MOTION; DISEASE EXACERBATION; DRUG SCREENING; ESOPHAGUS TUMOR; FOLLOW UP; GENE EXPRESSION REGULATION; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971657513     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7420     Document Type: Article

References (36)

1. Korets SB, Czok S, Blank SV, Curtin JP, Schneider RJ. Targeting the mTOR/4E-BP pathway in endometrial cancer. Clin Cancer Res. 2011; 17:7518-7528.
2. Ribback S, Cigliano A, Kroeger N, Pilo MG, Terracciano L, Burchardt M, Bannasch P, Calvisi DF, Dombrowski F. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget. 2015; 6:13036-13048. doi: 10.18632/oncotarget.3675.
3. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12:21-35.
4. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 2010; 7:209-219.
5. Zaytseva YY, Valentino JD, Gulhati P, Evers BM. mTOR inhibitors in cancer therapy. Cancer Lett. 2012; 319:1-7.
6. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009; 137:873-886.
7. Lai EY, Chen ZG, Zhou X, Fan XR, Wang H, Lai PL, Su YC, Zhang BY, Bai XC, Li YF. DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer. Asian Pac J Cancer Prev. 2014; 15:4589-4594.
8. Obara A, Fujita Y, Abudukadier A, Fukushima T, Oguri Y, Ogura M, Harashima S, Hosokawa M, Inagaki N. DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells. Biochem Biophys Res Commun. 2015; 460:1047-1052.
9. Gera J, Lichtenstein A. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk Lymphoma. 2011; 52:1857-1866.
10. Li H, Sun GY, Zhao Y, Thomas D, Greenson JK, Zalupski MM, Ben-Josef E, Sun Y. DEPTOR has growth suppression activity against pancreatic cancer cells. Oncotarget. 2014; 5:12811-12819. doi: 10.18632/oncotarget.2659.
11. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:409-414.
12. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008; 30:701-711.
13. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, Gera J, Lichtenstein A. DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Genes Cancer. 2014; 5:407-419. doi: 10.18632/genesandcancer.44.
14. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006; 9:313-325.
15. Pei L, Xie P, Zhou E, Yang Q, Luo Y, Tang Z. Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma. Mol Med Rep. 2011; 4:817-823.
16. Parvani JG, Davuluri G, Wendt MK, Espinosa C, Tian M, Danielpour D, Sossey-Alaoui K, Schiemann WP. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia. 2015; 17:317-328.
17. Duan S, Skaar JR, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, Pagano M. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol Cell. 2011; 44:317-324.
18. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-386.
19. Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma. Br J Cancer. 2012; 106:876-882.
20. Boone J, Ten Kate FJ, Offerhaus GJ, van Diest PJ, Rinkes IH, van Hillegersberg R. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol. 2008; 61:909-913.
21. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007; 253:236-248.
22. Hou G, Zhang Q, Wang L, Liu M, Wang J, Xue L. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. Cancer Lett. 2010; 290:248-254.
23. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Current opinion in cell biology. 2010; 22:169-176.
24. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009; 2:45.
25. Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Anti-cancer drugs. 2013; 24:889-898.
26. Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, Hu Y, Li L, Dong B, Li Z, Ji J. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anti-cancer drugs. 2014; 25:1129-1140.
27. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS biology. 2009; 7:e38.
28. Corominas-Faja B, Cufi S, Oliveras-Ferraros C, Cuyas E, Lopez-Bonet E, Lupu R, Alarcon T, Vellon L, Iglesias JM, Leis O, Martin AG, Vazquez-Martin A, Menendez JA. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell cycle. 2013; 12:3109-3124.
29. Tseng CN, Hong YR, Chang HW, Yu TJ, Hung TW, Hou MF, Yuan SS, Cho CL, Liu CT, Chiu CC, Huang CJ. Brefeldin A reduces anchorage-independent survival, cancer stem cell potential and migration of MDA-MB-231 human breast cancer cells. Molecules. 2014; 19:17464-17477.
30. Shi X, Gipp J, Bushman W. Anchorage-independent culture maintains prostate stem cells. Developmental biology. 2007; 312:396-406.
31. Fang MZ, Liu C, Song Y, Yang GY, Nie Y, Liao J, Zhao X, Shimada Y, Wang LD, Yang CS. Over-expression of gastrin-releasing peptide in human esophageal squamous cell carcinomas. Carcinogenesis. 2004; 25:865-871.
32. Zhao Y, Xiong X, Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 2011; 44:304-316.
33. Xie B, Zhou J, Shu G, Liu DC, Chen J, Yuan L. Restoration of klotho gene expression induces apoptosis and autophagy in gastric cancer cells: tumor suppressive role of klotho in gastric cancer. Cancer Cell Int. 2013; 13:18.
34. Yang ZT, Li Z, Wang XG, Tan T, Yi F, Zhu H, Zhao JP, Zhou XF. Overexpression of Long Non-Coding RNA ZXF2 Promotes Lung Adenocarcinoma Progression Through c-Myc Pathway. Cellular physiology and biochemistry. 2015; 35:2360-2370.
35. Gibert B, Hadchity E, Czekalla A, Aloy MT, Colas P, Rodriguez-Lafrasse C, Arrigo AP, Diaz-Latoud C. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene. 2011; 30:3672-3681.
36. Zhou X, Li D, Wang X, Zhang B, Zhu H, Zhao1 J. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Oncotarget. 2014; 6:3111-3122. doi: 10.18632/oncotarget.3076.